YSYilin Sun

Yilin Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yilin Sun has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Alex Lyakhovich

    Sabanci University, Molecular Biology, Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Turkey

    1 shared publication
  • Andrea Feliciano

    Pathology Department, Biomedical Research in Cancer Stem Cells Group, Institut de Recerca Hospital Vall d'Hebron (VHIR), Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain

    1 shared publication
  • Aroa Soriano

    Childhood Cancer and Blood Disorders Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain

    1 shared publication
  • Arturo Evangelista

    Teknon Medical Centre-Quironsalud. Heart Institute, Barcelona, Spain

    1 shared publication
  • Christine B. Kern

    Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, USA

    1 shared publication
  • Cristina Mir

    Biomedical Research in Cancer Stem Cells Group, Vall d’Hebron Research Institute (VHIR), 08035 Barcelona, Spain

    1 shared publication

Latest Publications

  • Open Access

    Versican accumulation drives Nos2 induction and aortic disease in Marfan syndrome via Akt activation

    by María Jesús Ruiz-Rodríguez, Jorge Oller, Sara Martínez-Martínez, Iván Alarcón-Ruiz, Marta Toral, Yilin Sun, Ángel Colmenar, María José Méndez-Olivares, Dolores López-Maderuelo, Christine B Kern, et al.

    Thoracic aortic aneurysm and dissection (TAAD) is a life-threatening condition associated with Marfan syndrome (MFS), a disease caused by fibrillin-1 gene mutations. While various conditions causing TAAD exhibit aortic accumulation of the proteoglycans versican (Vcan) and aggrecan (Acan), it is unclear whether these ECM proteins are involved in aortic disease. Here, we find that Vcan, but not Acan, accumulated in Fbn1 C1041G/+ aortas, a mouse model of MFS. Vcan haploinsufficiency protected MFS mice against aortic dilation, and its silencing reverted aortic disease by reducing Nos2 protein expression. Our results suggest that Acan is not an essential contributor to MFS aortopathy. We further demonstrate that Vcan triggers Akt activation and that pharmacological Akt pathway inhibition rapidly regresses aortic dilation and Nos2 expression in MFS mice. Analysis of aortic tissue from MFS human patients revealed accumulation of VCAN and elevated pAKT-S473 staining. Together, these findings reveal that Vcan plays a causative role in MFS aortic disease in vivo by inducing Nos2 via Akt activation and identify Akt signaling pathway components as candidate therapeutic targets.


  • Open Access

    miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer

    by Andrea Feliciano, Yoelsis Garcia-Mayea, Luz Jubierre, Cristina Mir, Manuela Hummel, Josep Castellvi, Javier Hernández-Losa, Rosanna Paciucci, Irene Sansano, Yilin Sun, et al.

    Lung cancer is one of the most aggressive tumours with very low life expectancy. Altered microRNA expression is found in human tumours because it is involved in tumour growth, progression and metastasis. In this study, we analysed microRNA expression in 47 lung cancer biopsies. Among the most downregulated microRNAs we focussed on the miR-99a characterisation. In vitro experiments showed that miR-99a expression decreases the proliferation of H1650, H1975 and H1299 lung cancer cells causing cell cycle arrest and apoptosis. We identified two novel proteins, E2F2 (E2F transcription factor 2) and EMR2 (EGF-like module-containing, mucin-like, hormone receptor-like 2), downregulated by miR-99a by its direct binding to their 3′-UTR. Moreover, miR-99a expression prevented cancer cell epithelial-to-mesenchymal transition (EMT) and repressed the tumourigenic potential of the cancer stem cell (CSC) population in both these cell lines and mice tumours originated from H1975 cells. The expression of E2F2 and EMR2 at protein level was studied in 119 lung cancer biopsies. E2F2 and EMR2 are preferentially expressed in adenocarcinomas subtypes versus other tumour types (squamous and others). Interestingly, the expression of E2F2 correlates with the presence of vimentin and both E2F2 and EMR2 correlate with the presence of β-catenin. Moreover, miR-99a expression correlates inversely with E2F2 and directly with β-catenin expression in lung cancer biopsies. In conclusion, miR-99a reveals two novel targets E2F2 and EMR2 that play a key role in lung tumourigenesis. By inhibiting E2F2 and EMR2, miR-99a represses in vivo the transition of epithelial cells through an EMT process concomitantly with the inhibition of stemness features and consequently decreasing the CSC population.